IAVI

📢 “Many EIDs are being underestimated,” stated Swati Gupta, Ph.D., in a recent interview with Global Health Hub Netherlands. As IAVI’s Vice President and Head of Emerging Infectious Diseases, Gupta is attuned to the public health challenges posed by the global spread of #EIDs — including Lassa fever, Marburg virus, and Sudan Ebolavirus. According to Gupta, these diseases cannot be tackled without addressing broader pandemic preparedness initiatives and healthcare equity concerns. The interview further highlights IAVI’s efforts to promote local capacity strengthening and develop globally accessible vaccines, with the support of the Dutch Ministry of Foreign Affairs and the Dutch Global Health Hub. Read the full article to learn more: https://ow.ly/vrjC50SqtWS

#HIVprevention initiatives must represent and center LGBTQIA communities, researchers, advocates, and policymakers—this #Pride and always. 🌈 Through the ADVANCE partnership (USAID), IAVI supports key research and policy efforts impacting LGBTQIA communities across sub-Saharan Africa. Check out and amplify these resources. ⬇️ - National Guidance on Integrating Mental Health (2022): https://ow.ly/683350SprPB - Key Population Size Estimation (KPSE) in Kenya (2022): https://ow.ly/CfnJ50SprPF - JIAS Supplement: Engagement of African men and transgender women who have sex with men in HIV research (2020): https://ow.ly/MgzG50SprPz - National Implementation Guidelines for HIV and STI Programming Among Young Key Populations (2018): https://ow.ly/eQqY50Sps4n - National Violence Prevention and Response Protocol - Kenya (2017): https://ow.ly/Nx5V50Sps7Z - Respect, Protect, Fulfill: MSM Research Guidance (2015): https://ow.ly/r5hy50SprPE

IAVI congratulates our partner PREVAIL in Liberia on starting vaccinations in a Phase 2a clinical trial of IAVI’s Lassa fever vaccine candidate! PREVAIL expects to enroll 204 participants at the JFK Hospital in Monrovia, Montserrado County. This Phase 2a study is the next step of IAVI and CEPI (Coalition for Epidemic Preparedness Innovations)'s Lassa vaccine development partnership, launched in 2018. Importantly, it’s the most advanced clinical trial of a Lassa vaccine to date. Vaccinations are ongoing in Nigeria, and we expect to enroll additional participants in Ghana. Lassa fever is one of the pathogens in the World Health Organization R&D Blueprint list of epidemic threats needing urgent R&D action. No vaccine is available for this viral hemorrhagic illness, and treatment is limited, despite seasonal outbreaks and high case fatality rates. Read more: https://lnkd.in/dFwNeHrf

IAVI and partners in the EDCTP-funded UPTAKE study are proud to share a the first publication from Kenneth R. Katumba. Kenneth is based at MRC/UVRI & LSHTM Uganda Research Unit and one of two UPTAKE PhD candidates enrolled at London School of Hygiene and Tropical Medicine, U. of London. The paper, 'Understanding the contexts in which female sex workers sell sex in Kampala, Uganda: a qualitative study' discusses the value of researchers and implementers in considering the differences in the contexts, challenges, and risks of where women sell sex to design innovative interventions and programs that reach and include all women. 📰 Read it at: https://lnkd.in/e6irR3pE Busara | KAVI Institute of Clinical Research (KAVI-ICR) | Global Health EDCTP3

Join us on our journey as we prepare for IAVI’s first Phase 2b clinical trial. In our latest Meet the Scientist podcast episode, we sat down with Elana Van Brakel, medical director at IAVI in Cape Town, South Africa, to explore IAVI’s engagement in the development of the MTBVAC TB vaccine candidate that is set to enter a Phase 2b clinical trial in adolescents and adults in sub-Saharan Africa later this year. Tune in to this episode to discover how Elana and IAVI’s TB team are preparing for this milestone trial. 🌐🔬 #SciencePodcast #newTBvaccines #YesWeCanEndTB 🔗 https://lnkd.in/eg84JUh5

Stay up to date with IAVI's work across HIV, tuberculosis, and emerging infectious diseases. Sign up for our newsletter or IAVI Report at www.iavi.org/subscribe!

Congratulations to our partners Biofabri and TBVI on their recent partnership announcement with the European Health and Digital Executive Agency, which will accelerate the development of the MTBVAC #tuberculosis #vaccine candidate. Last year, tuberculosis was the world's deadliest infectious disease. Effective new TB vaccines have the potential to save millions of lives, and additional support for their development is wonderful news. https://lnkd.in/ezrJ_ZfC

The immune system can make antibodies against HIV, but most of them aren’t very effective at eliminating or neutralizing the virus. There is, however, a small minority of people living with HIV whose B cells make broadly neutralizing antibodies, or #bnAbs. These bnAbs are better at neutralizing many different viral variants, yet they only rarely develop. James Voss, an investigator in the Department of Immunology and Microbiology at Scripps Research, is trying to overcome this by using gene editing technologies to reprogram B cells to make bnAbs against HIV. Will this be a route to a functional cure? Find out more in our new IAVI Report: https://lnkd.in/eEZ-vBBk

This Wednesday, June 19 marks #Juneteenth. At IAVI, we have chosen to close all our offices in acknowledgment that anti-Black racism, colonialism, and slavery continue to impact communities globally. By taking this day to reflect, learn, and commemorate, we reaffirm our dedication to creating a more inclusive and equitable future for all.

Don’t miss out on the 7th Global Forum on TB Vaccines this October! We’re honored to welcome Dr. Ethel Maciel, Secretary of Health Surveillance & Environmental Health, Ministry of Health, Brazil and Dr. David Lewinsohn, Chair, Stop TB Partnership Working Group on New TB Vaccines, as co-chairs for the 7th Global Forum on TB Vaccines. Dr. Maciel, a champion of Brazil’s commitment to #newTBVaccines, and Dr. Lewinsohn, with decades of TB vaccine research and advocacy expertise, bring invaluable guidance to maximize the impact of this important event. Registration is now open, with tiered pricing for participants from high-income countries, lower- and middle-income countries, and early bird rates available until July 31. A limited amount of travel and registration support is also available for students, post-docs, early career researchers, advocates, affected communities, and participants from lower- and middle-income countries.   🔗 Learn more this event at https://lnkd.in/eAz-J6c7 Stop TB Partnership Working Group on New TB Vaccines | TuBerculosis Vaccine Initiative (TBVI) | Ministério da Saúde | REDE-TB - Rede Brasileira de Pesquisas em Tuberculose | Stop TB Partnership